H35 (Inqovi cedazuridine 100 mg / decitabine 35 mg)
Generic Name: cedazuridine/decitabine
Pill with imprint H35 is Red, Elliptical/Oval and has been identified as Inqovi cedazuridine 100 mg / decitabine 35 mg. It is supplied by Taiho Oncology, Inc.
Inqovi is used in the treatment of myelodysplastic syndrome and belongs to the drug class antineoplastic combinations. Inqovi cedazuridine 100 mg / decitabine 35 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for H35
Inqovi
- Generic Name
- cedazuridine/decitabine
- Imprint
- H35
- Strength
- cedazuridine 100 mg / decitabine 35 mg
- Color
- Red
- Shape
- Elliptical/Oval
- Availability
- Prescription only
- Drug Class
- Antineoplastic combinations
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Taiho Oncology, Inc.
- Manufacturer
- Otsuka Pharmaceutical Co., Ltd.
- National Drug Code (NDC)
- 64842-0727
Related Images for "H35"
More about Inqovi (cedazuridine / decitabine)
- Side effects
- Drug interactions
- Dosage information
- During pregnancy
- Drug images
- Pricing & coupons
- En español
- Drug class: antineoplastic combinations
- FDA approval history
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.